New to peptides? Start with the foundations ->
The dad-test answer
Sildenafil is the workhorse for erectile dysfunction - it improves blood flow to the penis but does nothing for desire. Bremelanotide (PT-141) is a melanocortin-receptor agonist that acts in the brain on sexual desire and arousal. For mechanical ED that responds to PDE5 inhibitors, sildenafil is the answer. For low desire or PDE5 non-response, bremelanotide is the molecule. They're complementary, not competitors - some men run both.
Who wins for what
| Use case | Who wins, and why |
|---|---|
| erectile dysfunction with intact desire |
sildenafil FDA-approved for ED since 1998; reliable peripheral vasodilation that produces erection in response to normal sexual stimulation. |
| low desire or libido issue |
bremelanotide Melanocortin-receptor agonism in the CNS is the mechanism that drives the desire signal; sildenafil does nothing for libido. |
| PDE5 inhibitor non-responders |
bremelanotide Safarinejad 2008 showed about one-third of PDE5 non-responders had improved sexual response on bremelanotide; the two drugs work via different pathways. |
| FDA-approved indication for men |
sildenafil Viagra is FDA-approved for ED in men; Vyleesi is FDA-approved only for premenopausal women with HSDD - any male use of bremelanotide is off-label. |
What the head-to-head data shows
Sildenafil is not a peptide - it's a phosphodiesterase-5 inhibitor that prolongs nitric-oxide-mediated vasodilation in penile tissue. We cover it because patients with sexual function issues compare them directly. The Viagra evidence base is enormous; FDA approval came in 1998 based on multiple Phase 3 trials. Bremelanotide is a synthetic melanocortin-receptor agonist - the molecule was originally developed by Palatin Technologies; FDA approved it as Vyleesi in 2019 for premenopausal HSDD in women based on the RECONNECT trials. The male-use evidence is older and smaller - Safarinejad and Hosseini 2008 (J Urol) randomized 360 men with sildenafil-refractory ED to intranasal bremelanotide vs placebo and reported significantly improved erectile and intercourse-satisfaction outcomes. Palatin pursued co-administration with PDE5 inhibitors in Phase 2 for combination ED therapy; the program was paused, and male bremelanotide use in 2026 is off-label gray-market.
Our honest call
These solve different problems. For mechanical ED in a man whose libido is intact and who responds to PDE5 inhibitors, sildenafil is the answer - cheaper, generic, oral, FDA-approved, and well understood. For a man with low desire (regardless of erection quality), or for the PDE5 non-responder, bremelanotide is the molecule with a different mechanism worth trying. The combination has real evidence too - Palatin's Phase 2 and the Safarinejad data both support that bremelanotide + sildenafil produces a stronger response than sildenafil alone. The honest framing: bremelanotide for men is off-label in 2026, sourcing matters, and clinic-supervised dosing reduces the risk of the dose-related side effects (transient blood pressure increase, nausea, flushing). Read the PT-141 starter guide for the bremelanotide side.
Sources and citations
- Safarinejad and Hosseini, Salvage of sildenafil failures with bremelanotide, J Urol 2008 (PMID 18206165)
- FDA Viagra (sildenafil) prescribing label (approved Mar 1998)
- FDA Vyleesi (bremelanotide) prescribing label (approved Jun 2019)
- RECONNECT-301 and RECONNECT-302 Phase 3 trials in HSDD, Obstet Gynecol 2019
- Palatin Technologies bremelanotide + PDE5i combination program
Where to go next
- Full PT-141 directory entry
- PT-141 dosing breakdown
- What are peptides - if you skipped the foundation
- All Protocol One comparisons
- How peptides actually work
- Subscribe to the dispatch
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine. None of this replaces a doctor. Peptides are gray-market in the US for most uses. Talk to a real prescriber before you change anything.